Theravance Biopharma Inc Forecast, price target & analysts
Theravance Biopharma Inc Target price 2026 - Analyst rating & recommendation
Theravance Biopharma Inc Classifications & Recommendation:
Theravance Biopharma Inc Price Target
| Target Price | $27.54 |
| Price | $18.15 |
| Potential |
51.74%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Theravance Biopharma Inc 2027 .
The average Theravance Biopharma Inc target price is $27.54.
This is
51.74%
register free of charge
$44.10
142.98%
register free of charge
$13.13
27.66%
register free of charge
|
|
| A rating was issued by 12 analysts: 9 Analysts recommend Theravance Biopharma Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Theravance Biopharma Inc stock has an average upside potential 2027 of
51.74%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 64.38 | 109.95 |
| 12.12% | 70.78% | |
| Net Margin | -87.64% | 89.08% |
| 8.82% | 201.65% |
9 Analysts have issued a sales forecast Theravance Biopharma Inc 2025 . The average Theravance Biopharma Inc sales estimate is
This results in the following potential growth metrics:
9 Theravance Biopharma Inc Analysts have issued a net profit forecast 2025. The average Theravance Biopharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.16 | 1.93 |
| 16.00% | 266.38% | |
| P/E | 9.39 | |
| EV/Sales | 5.66 |
9 Analysts have issued a Theravance Biopharma Inc forecast for earnings per share. The average Theravance Biopharma Inc EPS is
This results in the following potential growth metrics and future valuations:
Theravance Biopharma Inc...
Current Theravance Biopharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Dec 03 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Nov 26 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
| Jones Trading |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Dec 03 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Nov 26 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2025 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jun 27 2025 |
|
Locked
Jones Trading:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 27 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
